The Department of Health and Human Services, through the National Institutes of Health (NIH), announces a funding opportunity for projects focused on advancing drug repositioning and combination therapy development for Alzheimer's Disease (AD) and related dementias (ADRD). The initiative invites applications that utilize computational and experimental approaches to rigorously test FDA-approved drugs or investigational compounds currently misappropriated for other conditions, aimed at demonstrating efficacy for AD/ADRD. The goal is to support in-vivo and in-vitro proof-of-concept studies to establish synergies and optimize therapeutic strategies. While drug repurposing has potential advantages like reduced development costs and timeframes, previous efforts in AD treatments have been largely unsuccessful, underlining the need for a more systematic approach. The program encourages collaborative partnerships between academia and industry, and emphasizes compliance with NIH policies for research rigor and reproducibility. Applications can receive up to $1 million annually, with a funding pool of $6 million intended for 4-5 awards. The application process has defined deadlines and submission requirements designed to ensure thorough review and compliance with open research practices, stressing the importance of data management and sharing throughout the project lifespan.